United Therapeutics Q3 2026: Record Revenue, EPS Miss Explained

United Therapeutics posted record quarterly revenue of $832.5 million in Q3 2026, beating expectations against the $781.1 million consensus estimate. Tyvaso DPI led the top line with 13% growth, and Orenitram added an 11% gain. Those gains more than offset declines in Nebulized Tyvaso and Remodulin.

GAAP EPS came in at $5.71, missing expectations against the $6.04 consensus, on a one-time accounting event rather than deteriorating demand. The acquisition of Thymmune Therapeutics triggered a $130.0 million in-process research and development charge that was nondeductible for tax purposes, pushing the effective tax rate to 31% from 23% a year earlier. A $66.5 million litigation accrual reversal tied to the Sandoz matter softened the blow but was not enough to offset the tax hit.

The recent EPS history is mixed: the company beat estimates in Q3 and Q4 2025 as well as Q2 2026, but fell short in Q4 2024, Q2 2025, and Q1 2026. The pattern shows how sensitive reported earnings are to one-time charges, even when the underlying business is growing.

The board authorized a new $2.0 billion share repurchase program through October 21, 2027, shortly after the prior $2.0 billion March 2026 program was fully utilized. That prior program was executed through accelerated share repurchase agreements, including a September 2026 ASR of $477.6 million with Citi whose final settlement is expected in Q4 2026.

CEO Martine Rothblatt said the company is entering a period of extraordinary growth, advancing therapies designed to exponentially increase the number of patients served. COO Michael Benkowitz described the current pipeline as the strongest growth outlook in the company's history, pointing to cardiopulmonary and respiratory opportunities he called rapidly approaching. R&D expense rose 119% to $279.2 million, reflecting both the Thymmune acquisition and increased spending on manufactured organ and organ alternative projects.